Form 4: Centessa Pharmaceuticals CEO Saurabh Saha Sells Shares Under 10b5-1 Trading Plan
SEC Form 4 Filing
Centessa Pharmaceuticals CEO Saurabh Saha sold 55,000 ordinary shares at an average price of $17.4374, pursuant to a pre-arranged Rule 10b5-1 trading plan.
Summary
- On December 20, 2024, Saurabh Saha, the CEO of Centessa Pharmaceuticals plc, sold 55,000 ordinary shares of the company.
- The sales were executed under a Rule 10b5-1 trading plan adopted on May 16, 2024.
- The shares were sold at prices ranging from $17.12 to $17.90, with a weighted average price of $17.4374.
- Following the transaction, Saha directly owns 520,661 ordinary shares and indirectly owns 38,000 shares through a trust.
- Saha and his spouse serve as trustees for the trust holding the indirectly owned shares.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing reporting a share sale by the CEO. It doesn't inherently convey positive or negative sentiment, as it's a routine disclosure.
Industry Context
Sales by executives are a normal part of corporate governance. The use of a 10b5-1 plan suggests the sales were pre-planned and not based on any inside information.
Stakeholder Impact
- The share sale could have a minor impact on shareholder sentiment, depending on how the market interprets the CEO's actions.
Key Dates
| Date | Description |
|---|---|
| May 16, 2024 | Date the Reporting Person adopted the Rule 10b5-1 trading plan |
| December 20, 2024 | Date of the share sale transaction |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.